Center-Authored Papers

Filters: Author is Crawford, E David  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, Abnet CC, Huang W-Y, Kibel AS, Crawford DE et al..  2009.  Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.. Carcinogenesis. 30(5):769-76. Abstract
B
Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford DE et al..  2012.  Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.. Urology. 79(3):633-7. Abstract
C
Crawford DE, Higano CS, Shore ND, Hussain M, Petrylak DP.  2015.  Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.. The Journal of urology. 194(6):1537-47. Abstract
Crawford DE, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, Keane TE, Koo PJ, Gomella LG, O'Sullivan JM et al..  2017.  The Role of Therapeutic Layering in Optimizing Treatment for Patients with Castration-Resistant Prostate Cancer (RADAR II).. Urology. Abstract
Crawford DE, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A.  2015.  Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.. The Canadian journal of urology. 22(6):8048-55. Abstract
Crawford DE, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger RE, Keane TE, Sieber P et al..  2014.  Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer.. Urology. Abstract
Crawford DE, Shore ND, Petrylak DP, Higano CS, Ryan CJ.  2017.  Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.. Therapeutic advances in medical oncology. 9(5):319-333. Abstract
F
Flaig TW, Tangen CM, Hussain MHA, Stadler WM, Raghavan D, Crawford DE, Glodé ML.  2008.  Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(9):1532-6. Abstract
G
Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles RA, Strom SS, Rybicki BA et al..  2016.  Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.. Nature communications. 7:10979. Abstract
H
Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford DE.  2008.  Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.. Cancer. 112(10):2181-7. Abstract
Higano CS, Crawford DE.  2011.  New and emerging agents for the treatment of castration-resistant prostate cancer.. Urologic oncology. 29(6 Suppl):S1-8. Abstract
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford DE, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ et al..  2013.  Intermittent versus continuous androgen deprivation in prostate cancer.. The New England journal of medicine. 368(14):1314-25. Abstract
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
L
Lara PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford DE.  2009.  Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.. The Journal of urology. 181(2):512-6;discussion516-7. Abstract
Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford DE.  2009.  Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer.. Urologic oncology. 27(2):155-9. Abstract
Lippman SM, Klein EA, Goodman PJ, Lucia SM, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano MJ, Hartline JA et al..  2009.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. JAMA : the journal of the American Medical Association. 301(1):39-51. Abstract
M
Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF et al..  2011.  Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917.. Cancer prevention research (Philadelphia, Pa.). 4(11):1761-9. Abstract
Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S et al..  2008.  Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(1):112-20. Abstract
S
Sartor OA, Tangen CM, Hussain MHA, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford DE.  2008.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).. Cancer. 112(11):2393-400. Abstract
Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman BH, Wood DP, deVere White RW, Vogelzang NJ, Trump DL, Natale RB et al..  2011.  Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU international. 108(5):693-699. Abstract
Shore ND, Crawford DE, Higano CS, Sartor O.  2016.  Advancing Treatment Strategies in Metastatic Castration-resistant Prostate Cancer: The Urologists Role.. Urology.
Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford DE.  2008.  The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794.. The Journal of urology. 180(6):2453-7;discussion2458. Abstract
T
Tangen CM, Hussain MHA, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford DE, Vogelzang NJ et al..  2012.  Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346).. The Journal of urology. 188(4):1164-9. Abstract
Thompson IM, Tangen CM, Paradelo J, Lucia SM, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G et al..  2009.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.. The Journal of urology. 181(3):956-62. Abstract
Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A et al..  2017.  Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.. Annals of internal medicine. Abstract